Salus Biomed obtained Category III medical device registration from China’s NMPA for its Saluseq Nimbo rapid next‑generation sequencer, clearing the platform for clinical applications in China. The reversible‑terminator sequencer provides single‑run results in as little as 2.2 hours (SE50) and offers high Q30 accuracy (>90%), targeting pathogen detection, cancer genomics, reproductive health and genetic screening. Salus previously secured CE‑IVD certification for the platform and obtained NMPA approval last year for another reversable terminator product. The company raised Series B1 financing in October and positions the Nimbo approval as a step toward wider clinical adoption in China’s fast‑growing molecular diagnostics market.